• Technology that improves bioavailability of orally ingested cannabinoids
• Safer approach that mitigates risks from carcinogens
• Generates revenue by out-licensing its technology internationally

Announcement of a new government initiative to reduce the level of nicotine in cigarettes to nonaddictive levels is good news for Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP). Less addictive cigarettes mean less dependence on smoking as a delivery system, not only for nicotine but other substances like cannabinoids, which is why the folks at Lexaria are cheering the Food and Drug Administration (FDA) on. This innovative bioscience company has developed technology that offers a safer and more efficient delivery system for bioactive compounds, including cannabinoids.

The idea of reducing nicotine levels has been knocking around for a while. Writing in the New England Journal of Medicine in 1994, Dr. Neal Benowitz, a professor of medicine at the University of California, San Francisco, proposed the idea, according to Scientific American (http://dtn.fm/StK3t). Lower levels of nicotine might make smoking less of a habit and so reduce the toll of the many carcinogens (cancer-causing agents) found in tobacco smoke. Less nicotine would also reduce the risks associated with nicotine itself. The substance is highly addictive, and heavy long-term use may damage arteries, increasing the risk of stroke. Nevertheless, the dangers posed by its use pale in comparison to those caused by the arsenic, benzene, lead and other carcinogens that permeate tobacco smoke.

In 1994, though, the FDA did not have the authority to set nicotine levels for cigarettes. That changed after the passage of the Tobacco Control Act in 2009, which gave the agency power to reduce, but not eliminate altogether, the amount of nicotine in cigarettes. Now, the FDA is exercising its mandate. Its new commissioner, Scott Gottlieb, believes that by making smoking less addictive, more Americans will buck the habit and avoid the peril of developing cancer. In addition, reduced nicotine levels in cigarettes may ultimately cause a divorce from smoking. After all, there are a variety of alternative ways to ingest nicotine, including vaping and chewing gum.

If the smokescreen is removed from cigarettes, they will be seen for what they are: simply, a hazardous delivery system for nicotine, albeit an effective one, no doubt. And for those who must have their nicotine, there are much safer ways to get it, an argument that applies equally well to cannabinoids. Lexaria has proprietary technology for improved delivery of bioactive compounds, which offers a no-smoking safer way to administer cannabinoids.

The company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, a decided advantage, since cannabinoids are not absorbed very well by the body’s gastrointestinal tract. The Lexaria process improves bio-absorption of cannabinoids to levels that equal smoking, and onset has been reported as occurring within 15-20 minutes, as opposed to 60-120 minutes for edibles. The company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for delta-9-tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

The Lexaria technology, which also improves taste, has the potential to improve the absorption and potency of a variety of medical products, including vitamins and analgesics. The company plans to generate revenue by out-licensing its technology internationally.

For more information, including a stock chart and videos, please visit www.LexariaEnergy.com/investors

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• MKGI just announced $3 Million private placement
• Insiders took down over 20 percent of the offering
• Insider actions are a valuable barometer of future valuations
• MKGI changing trajectory of booming alternative lodging rentals (ALR) market

Tips for beating the market come and go, but one indicator has consistently held up. If insiders such as executives, directors or others with familiarity of a public company are buying or selling shares, investors should consider doing the same thing. Analytical research has repeatedly shown that insider trading activity is a valuable barometer of future stock valuation and market sentiment.

Monaker Group (OTCQB: MKGI), a technology-driven travel company, just announced its entry into definitive documentation relating to a private placement of equity financing totaling in excess of $3.0 million in gross proceeds (http://dtn.fm/B3j1d). The real eye opener in this announcement is that “Certain insiders and board members participated in the offering, representing $635,000 or approximately 21 percent of the transaction.” It’s not only a vote of confidence by the insiders but also time for astute investors to take notice when “certain insiders and board members” take down over 20 percent of a private placement financing.

A closer look at Monaker gives some indication of insider predilections. Monaker Group is a technology-driven travel company focused on delivering innovation to the alternative lodging rentals (ALR) market. The Monaker Booking Engine can instantly book any of more than 1.4 million vacation rental homes, villas, chalets, apartments, condos, resort residences and castles. The key to MKGI’s strategy is to move ALR into the mainstream travel industry, offering instant confirmation, something relatively new to ALR. Then, by combining instant-confirmation options with all other traditional travel options, MKGI will be able to offer a true all-in-one online booking site and alter the course of the booming alternative lodging rentals market.

As Bill Kerby, CEO of Monaker, stated in a recent press release, “Since the introduction of our proprietary booking engine last year, we’ve received growing interest by both product suppliers and potential distribution partners. This interest has been buoyed by strengthening consumer demand for instantly-bookable ALRs.”

With decades of travel industry experience and relationships, Monaker targets volume travel booking entities. The company expects large B2B white label use of the Monaker Booking Engine into mainstream travel channels such as airlines, travel agent platforms and cruise organizations. Monaker believes white label use (other companies branding and using the engine as their own) will ultimately generate over 90 percent of the company’s future growth.

The enticement for travel agencies and large travel bookers is that the Monaker Booking Engine provides a customizable instant booking platform for ALR. By developing instant booking confirmation and integrating everything necessary to offer traditional hotels, travel, cruises, car rental and entertainment then combining it all with ALR into one full-service site for consumers, Monaker intends to change the trajectory of the ALR travel industry.

Monaker is on a path that may well disrupt the status quo of the fastest growing segment of the nearly $700 billion travel market. Company insiders increased their own positions and purchased 20 percent of the private placement for a reason, astute investors should take notice.

For more information about the company, visit www.MonakerGroup.com

• eLearning programs to close the skills gap
• Shortage of electricians on the horizon
• Building an international training brand for technical vocations and trades

Although the details have not been published to date, Infrastructure Week, in early June, kept alive the hopes stemming from President Trump’s campaign promise to spend $1 trillion updating America’s aging infrastructure. If that grand initiative gets underway, thousands of skilled workers in a variety of fields will be required, but are they likely to be there when we need them? With the Bureau of Labor Statistics (BLS) reporting the national unemployment rate for June 2017 at 4.4 percent (http://dtn.fm/uIE09), employers are finding it increasingly difficult to find the right hires, and millions of jobs remain vacant. Yet many of the unemployed cannot fill those positions, since they lack the required skills. To close this skills gap and make American workers infrastructure-ready, ProBility Media Corp. (OTCQB: PBYA) is offering a comprehensive suite of eLearning and training programs. The Houston, Texas-based company is building the first full service eLearning training and career advancement brand for technical vocations and trades.

Those infrastructural projects rebuilding roads and bridges and dams are going to need thousands of well-trained HVAC (heating, ventilation & air-conditioning) technicians, plumbers, and electricians. Electricians, particularly, are forecast to be in high demand. The BLS estimates that about 86,000 additional electricians will be needed by 2024. This rise in quantity demanded over the next seven years will be driven by the wiring of new homes and businesses, as well as an overall growth of the construction industry.

Due to these developments, the electrician field is projected to see a much faster than average growth rate of 14 percent in the years ahead, resulting in 85,900 new jobs by 2024. In addition, the BLS notes that because many employers have reported “difficulty finding qualified applicants,” a shortage of electricians is looming (http://dtn.fm/Wd04j). This shouldn’t be. The median income for electricians is $51,880, higher than that for construction trades workers and higher than the median for all occupations. Electricians, it seems, make livable wages in a high-growth career.

With ProBility’s comprehensive suite of eLearning and training programs, budding electricians can build their resumes and their skills to take on those lucrative roles. But the company has positioned itself as a key industrial training resource not only for individuals, but for small- and medium-size businesses (SMEs) and enterprise customers. To individuals and institutions alike, ProBility’s objective is to offer consistent high-quality training services and materials for education, testing, and career advancement.

ProBility is endeavoring to become one of the largest certification providers in the country, with programs in 22 states and a goal of servicing all 50. It is pursuing a roll-up strategy in the disparate vocational training space, acquiring and amalgamating educational services for a variety of skilled trades under one roof, a strategy that is already showing signs of success. Revenues for the quarter ended April 30, 2017, were $1.8 million, up 153 percent over same period 2016, and revenues for the first six months of the 2017 financial year, at $2.9 million, were just below whole year 2016 revenues of $3.1 million. If sales continue at this level, ProBility is on track to see top line revenue exceed $7 million for 2017. The bottom line will be a better-trained workforce ready and able to take America’s infrastructure into the 21st century.

For more information about the company, visit www.ProBilityMedia.com

Let us hear your thoughts: ProBility Media Corp. Message Board

• Good investment opportunities exist in the marijuana boom, but caution is urged
• Choosing companies with access to the legal medical marijuana space can help investors avoid the risk of changing regulations
• Algae Dynamics Corp. is focusing on cannabis oil extraction and medicine delivery systems to provide the medical benefits without having to smoke
• ADYNF is partnering with two major universities to research the use of cannabis oil extracts for cancers and novel mental health treatments

Everyone knows there is money to be made in marijuana these days. Americans already spend more on cannabis than ice cream each year, and Canadians are anticipating a combined market that may be larger than the entire domestic alcohol industry by 2020.

How and where to invest, however, is not that simple. An article titled “Investing in International Cannabis Markets” in CannaTech (http://dtn.fm/Fdos3) offers some advice to potential investors.

Savvy investors should keep several things in mind. Regulations are changing, and, while the general trend is toward legalization, it is best to look for companies operating in the legal medical marijuana market to avoid the risk of uncertain federal regulations. These types of investments are even better if the company is positioned to take advantage of recreational legalization, when and if it comes.

Algae Dynamics Corp. (OTCQB: ADYNF) is one such company focusing on the extraction of oils from hemp, cannabis and algae for use in unique health products and pharmaceuticals.

Algae Dynamics’ strategy initiative is to explore compounds extracted from cannabis and to focus on the development and formulation of products that combine the benefits of algae and cannabis oils. The company is targeting the human endocannabinoid system with algae and cannabis oil extracts. Endocannabinoids are found naturally in the human body.

The endocannabinoid system plays an essential mediating role in several physiologic systems, and receptors can be found throughout the central and peripheral nervous systems. Plant-based cannabinoids may offer a more natural way of treating various diseases including multiple sclerosis, arthritis, hypertension, memory loss, pediatric epilepsy and neuropathic pain (http://dtn.fm/6aBQK).

Algae Dynamics plans to leverage its expertise in algae oil extraction to produce cannabis oil extracts for use in non-smoke formulations that offer the health benefits of cannabis without the dangers of smoking. Once extracted, cannabis oil can be vaporized or made into tinctures.

Medically beneficial cannabis oil formulations are being researched by Algae Dynamics by way of partnerships with two major universities. The company has signed a research and product development agreement with the University of Waterloo (http://dtn.fm/tItD5) for a three-year, $600,000 program to investigate the use of cannabis oil in the treatment of colorectal, pancreas, breast and prostate cancers.

A four-year, C$1,000,000 agreement with the University of Western Ontario (http://dtn.fm/fpUx6) will fund research and product development on the use of cannabis derivatives as novel pharmacotherapies for mental health diseases such as depression, post-traumatic stress disorder, anxiety and schizophrenia.

With its entry into the North American cannabinoid market, which is expected to top $2 billion in consumer sales by 2020, Algae Dynamics is an intriguing investment opportunity for those seeking opportunities in this booming market.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

• Entering $30+ billion Chinese skin care market
• First and only CBD-based products to market
• Expects to capture huge share of new skin care products category

Any dispute over the efficacy of medical cannabis is settled science. Recent prestigious clinical studies have provided conclusive evidence that medical cannabinoids are effective medicine for a variety of diseases and ailments (http://dtn.fm/51coN). Cannabidiol (CBD) has been scientifically shown to be effective in the treatment of certain epilepsies, pain, inflammation and nausea, as well as providing relief from hangover, anxiety and stress.

It comes as little surprise then that cannabis may well possess skin healing properties. Cannabis is a known anti-inflammatory containing antioxidant and anti-aging elements. Hemp seed oil contains omega-3 and omega-6 fatty acids. These essential fatty acids can enhance complexion by improving the skin’s texture and softness. They keep skin cells moist by reducing the amount of water lost through the epidermis, and they also increase production of collagen, a protein that makes up connective tissue and is a structural building block of firm, healthy skin. The human endocannabinoid system utilizes multiple cannabinoid receptors, and a large number of these are actually found in the skin.

In spite of vast anecdotal evidence, hard science has not yet settled on the positive effects of CBD skin care. However, it took decades and overcoming wrong-headed preconceptions to scientifically prove the medical efficacy of CBD in multiple maladies. It should easily follow that there are underlying benefits of topical cannabis-based skin care products.

When looking for opportunity in this new arena, look to China, the second-largest consumer of skin care products in the world, generating nearly $30 billion in annual retail sales. The recent article “Investment Options in the Multi-Billion Dollar Medical Marijuana Industry” (http://dtn.fm/w4Mhs) highlighted ChineseInvestors.com (OTCQB: CIIX) entering the multi-billion Chinese skin care industry with the introduction of a new line of cannabidiol-based skin care products. The company has filed a record of its first line of hemp-infused skin care products with the China Food and Drug Administration (http://dtn.fm/eMv58) and expects to launch in the next couple months.

As the company stated in its press release, “Although ancient Chinese recognized the medicinal properties of the cannabis plant, CBD extract appears to be largely unrecognized in China today for its benefits, including but not limited to, its potential benefits to the largest visible human organ, the skin.”

When one considers how prevalent skin conditions are, it becomes clear that a safe, effective new treatment is likely to be embraced by a significant portion of the population. Understandably, the market potential is enormous. Not only is the market potential huge, the company anticipates capturing “100% of China’s market share in this novel skin care products category,” since, to its knowledge, no other manufacturers have entered the cannabis skin care product market in China.

Given the immense opportunity in CBD-based skin care and the multiple markets and products that ChineseInvestors.com is pursuing, it very well may be time to get some skin in the game.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Has patents in the United States and Australia and patents pending in more than 40 countries for proprietary technology easing how edible cannabinoids enter body
• Revenue stream comes from own products and 5-10% margin of gross sales from licensing technology to third parties
• Signed C$250,000 joint venture agreement with National Research Council (NRC) in Canada to research and find best methods for processing active agents in foods

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) already owns international patents for its proprietary intellectual property and has more global patents pending in the cannabis marketplace. It believes that the sub-sector of bioscience technology for edible CBDs will expand. It expects a new round of investors will be attracted to “plant-to-bloodstream” companies. Initially, it said, investors funded “seed-to-plant” companies.

The Kelowna, British Columbia, Canada-based food bioscience company is a technology disruptor for edible CBDs. It markets a high absorption hemp oil formula, protein energy bars, exotic teas and high absorption hemp oil capsules to help the human body absorb CBDs. In its June 2017 corporate presentation for investors (http://dtn.fm/3v1NR), Lexaria Bioscience noted that its focus is on researching and developing additional products for the edible cannabinoids market. It owns international patent rights and has pending patents for its technology changing the way cannabinoids enter the body.

This sub-sector is in its relative infancy as companies seeks to learn more about the medicinal potential for medical marijuana. Lexaria Bioscience is the only publicly traded company which has intellectual property in this sub-sector, covering non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and vitamins, according to a July 2017 market research report titled, “Biotech Players Lead the Growth Charge in the Legal Cannabis Market” (http://dtn.fm/ojRn1). The company has received for its proprietary technology its first patents in the United States and Australia and has patents pending in more than 40 countries globally.

Lexaria’s technology aims to improve the human body’s absorption of CBDs in the gastrointestinal tract. The process is effective, not just for CBDs, but also for other non-psychoactive cannabinoids. Patents are pending, too, for NSAIDs, nicotine and other molecules, per the research report.

By masking the bitter taste, reducing ingestion time and improving bio-absorption of CBD products, Lexaria Bioscience enjoys revenue streams from its own product line brands, such as Turbo CBD™, ViPova™, and Lexaria Energy Foods, as well as from licensing to third party partners at a 5-10% margin of gross sales.

Lexaria Bioscience has also just signed a C$250,000 collaborative research agreement with the National Research Council (NRC) of Canada for an 18-month term to investigate opportunities to evaluate and determine the best methods for processing lipophilic active agents within foods. The research will also study cannabinoids such as THC, vitamins, nicotine and NSAIDs. The result could be isolating a chemical or physical “fingerprint” identification to study Lexaria’s technology in consumer products, the company’s investor presentation said.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• China is now the world’s largest economy and on the brink of incredible growth
• Moxian is targeting owners of 75 million small- and medium-sized businesses in China with O2O tools to engage and convert online viewers to brick and mortar purchasers
• Social gaming, loyalty rewards and messaging allow Moxian to mine consumer data for clients’ benefit while driving revenue

Moxian, Inc. (NASDAQ: MOXC) is offering investors a unique opportunity to benefit from the growth of what is now the world’s largest economy. Moxian, a digital marketing company based in Shenzhen, China, is on the leading edge of e-commerce in China’s newly emerging private-based economy, offering merchants a way to convert online views into retail purchases at brick and mortar locations.

China became the world’s largest exporter in 2010, and, in 2014, surpassed the U.S. to become the largest economy in the world, according to Forbes (https://www.forbes.com/places/china/). The country is on the brink of incredible growth as it transitions into a consumer-based economy, according to Stephen Roach, former chairman of Morgan Stanley Asia (http://dtn.fm/3zOoD). Moxian is well-positioned to both drive the transition and benefit from it.

Moxian uses social media, entertainment and business intelligence to focus on the online-to-offline market (O2O). The company is targeting China’s 75 million small- and medium-sized businesses to help offline merchants reach more digitally-oriented customers using promotions such as games, rewards, loyalty programs and social events.

Moxian is in the process of converting more than 31,000 small market enterprises (SMEs) to paid clients with its Moxian+ Business app. The app allows businesses to interact with new and existing customers and uses a client’s consumer list to mine valuable data analytics and drive retail traffic into brick and mortar locations. Clients can create, manage and promote customized loyalty programs, ad campaigns and promotions.

For the 300,000 consumer users, the Moxian+ User app offers games, social loyalty programs and shopping, along with Mo-Talk, a proprietary voice chat service which helps clients and merchants interact.

Moxian projects its mobile advertising revenue in China to reach $3 million in 2017 and $6 million in 2018 – 24% of company sales. Spending on digital advertising in China has jumped to 57.2% of total ad dollars. SeeThruEquity (http://dtn.fm/AJ7rb) has projected that Moxian will reach $24.1 million in sales by fiscal year 2018.

For more information, visit the company’s website at www.Moxian.com

• Cashless payments continue growing
• Technology to handle debit and credit card payments
• Aptito restaurant management solution driving sales

The payment system has come a long way from the time when transactions were mainly settled in specie. In antiquity and during the medieval period, purses glittered with gold and silver coin. Then, paper money, used by the Chinese a thousand years before, began to appear in 17th century Europe. From the late Renaissance to the end of the 20th century, banknotes and, increasingly, checks were used to transfer funds and make payments. Now, with the internet girding the globe, these media are being replaced by electronic means, like those offered by innovative fintech, Net Element, Inc. (NASDAQ: NETE). This global financial company provides merchants with the technology to accept funds electronically through an omni-channel environment that includes both online and offline payments.

A dollar paid may be a dollar received, but not all payments are processed in the same way. A typical debit card transaction can actually be processed in two ways, online and offline, which terms, misleadingly, differ from their colloquial meanings. In an online transaction, a consumer authorizes a payment by keying in her PIN at the point-of-sale after swiping a debit card through a magnetic card reader. The transaction is approved in real time, the customer’s account is adjusted immediately, and money is transferred to the merchant’s account in two to three business days.

However, at present, processing debit transactions “online” is only available in the brick-and-mortar world where the consumer is physically present. Typically, you cannot do a PIN transaction on the internet, although already, ecommerce PIN debit solutions are starting to make their appearance. In an offline transaction, on the other hand, no PIN is involved. Instead, the consumer will be required to sign a receipt. Offline debit transactions are processed through the networks operated by credit card providers, such as Visa, MasterCard and American Express.

Whether it be online or offline, Net Element can handle it. The solutions offered by the company enable merchants of all sizes to accept and process over 100 different payment options in more than 40 currencies, including credit, debit and prepaid payments. Net Element also provides merchants with value-added services and technologies including integrated payment technologies, point-of-sale solutions, security solutions, fraud management, information solutions and analytical tools.

The company has been reporting very strong results for its North America Transaction Solutions (NATS) and Online Payment Solutions (OPS) divisions. In 2016, NATS revenues reached $42.1 million, an increase of 54 percent over 2015. Sales to small- and medium-sized enterprises (SMEs) were particularly good. The division’s product offerings include Aptito, a cloud-based Software-as-a-Service (SaaS) restaurant management solution. OPS also performed well. Revenues rose by 63 percent, in 2016, to reach $6.2 million. Total revenues for 2016 were $54.3 million, which represented a 35 percent year-over-year increase.

At its current stock price of $0.44, Net Element’s market cap is approximately $7.8 million, which is just 14 percent of 2016 revenues. SeeThruEquity, in an April 2017 report, set a target price of $2.45. In a world that is increasingly embracing cashless payments, Net Element is very likely to hit that target.

For more information, visit the company’s website at www.NetElement.com

• Cannabidiol (CBD) combats anxiety, inflammation, nausea and vomiting
• Low side-effect profile means high doses of cannabidiol can be used for treatment of schizophrenia, dementia, diabetes and nausea
• Lower doses promote and maintain health with anti-oxidative, anti-inflammatory and neuroprotective effects
• Lexaria Bioscience Corp. set to benefit from increasing interest in CBD as patented technology improves taste, rapidity and effectiveness of bioactive compounds including cannabinoids

A new scientific review of the safety and side effects of cannabidiol confirms and expands on the myriad known health benefits of cannabidiol and the compound’s lack of side effects.

The review, titled “An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies,” was published in the journal Cannabis and Cannabinoid Research in June. To view the full publication, visit: http://dtn.fm/cbd-clinical-overview-pdf.

Cannabidiol has a number of beneficial effects, the study states; it is anti-inflammatory, anxiolytic, antiemetic and antipsychotic. This can only increase the demand for cannabidiol (CBD) products and is good news for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria has patented a revolutionary lipophilic delivery method which allows accurate, timely delivery of cannabinoids without the need for users to smoke, vape or otherwise inhale the substance.

Lexaria out-licenses its proprietary technology for improved taste, increased speed and efficiency in the delivery of bioactive compounds, including cannabinoids. The special manufacturing process infuses CBD within lipids, which form the basis of the human endocannabinoid system. Lexaria Bioscience’s new process masks the undesirable taste of cannabidiol, which eliminates the need for added sugar and results in a healthier product.

The review’s authors, Iffland Kerstin and Grotenhermen Franjo, concluded that along with the beneficial effects, the safety profile of CBD is excellent. Chronic use and high doses of up to 1,500 mg per day have repeatedly shown to be well tolerated. Cannabidiol does not alter physiological parameters such as heart rate and blood pressure and does not adversely affect psychological and psychomotor functions, food intake or gastrointestinal transit.

The study’s authors reviewed clinical data and animal studies to extend and update a comprehensive survey by Bergamaschi et al. in 2011 on CBD safety and side effects; they concluded that CBD has a much better side effect profile than other drugs used for the treatment of epilepsy and psychotic disorders.

Several studies have shown cannabidiol to be effective in the treatment of epilepsy. In one study, CBD treatment reduced seizures by 45% in 261 young children who were not receiving relief from standard medications. In another study, CBD reduced the frequency of seizures by 39% in therapy-resistant epilepsy patients.

Cannabidiol has also been shown to have anti-anxiety effects equivalent to a standard dose of imipramine, a selective serotonin reuptake inhibitor sold as Tofranil and commonly used to treat anxiety and depression.

Studies have found that CBD reduces inflammation in the gastrointestinal system, treats symptoms of multiple sclerosis and helps with the management of glaucoma.

According to the study review, cannabidiol has also been shown to:

• help with cannabis withdrawal
• reduce heroin-seeking behaviors
• reduce psychotic symptoms in Parkinson’s patients
• reduce the likelihood of developing diabetes
• positively modulate the immune system in diseases such as multiple sclerosis, arthritis and diabetes
• reduce amyloid beta neuro-inflammation and prevent the development of a social recognition deficit in Alzheimer’s disease.
• reduce swelling and inflammation in arthritis
• prevent or slow the spread of certain types of aggressive cancer cells
• reduce weight gain
• reduce symptoms of psychiatric disorders such as psychosis and bipolar disorder

Cannabidiol is not the only substance which can be formulated and delivered via Lexaria’s revolutionary delivery method; the patented technology can be used for delivery of nicotine, vitamins, analgesics and a variety of other substances. Tests by an independent, third-party lab show that Lexaria’s technological process and lipid formulation improve intestinal absorption by as much as 500%.

Patents have been issued to the company in the U.S. and Australia protecting Lexaria’s intellectual property for the edible delivery of all non-psychoactive cannabinoids, including cannabinoid edibles. A variety of food and beverage formats are protected by the patent, including tea, coffee, cocoa powder, fresh foods and meats, dairy products, pastas, breads, seeds, nuts, spices, herbs, candies, flavorings and more.

Lexaria is primarily a B2B enterprise, and it is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the U.S., and abroad.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Oncology pipeline features significant safety/efficacy advantages
• Lead candidate poised for FDA acceleration due to significant unmet need in AML
• Broad-spectrum applicability of WP1066 & WP1122 portfolios of molecules

For preclinical oncology biopharma Moleculin Biotech, Inc. (NASDAQ: MBRX), the quest to deliver potentially revolutionary anti-cancer drugs to the market is enkindled by a close association with The University of Texas MD Anderson Cancer Center. This institution’s stated mission is nothing less than to make “cancer history,” and eliminate cancer on a global scale. Truly an American success story to be proud of, MD Anderson is one of the largest cancer centers in the world, employs some 20,000 people in Houston and Central Texas, and is ranked number one by U.S. News & World Report’s “Best Hospitals” when it comes to quality cancer treatment. The superbly integrated programs of patient care, research and prevention – for which MD Anderson is widely known – have massively helped to foster innovative thinking when it comes to wrangling some of the most ornery cancer types.

More Powerful, Novel, Safer, More Versatile Pipeline of OncoTech

Moleculin’s rapidly developing pipeline (some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center) consists of the company’s lead drug candidate Annamycin, which targets relapsed or refractory acute myeloid leukemia (AML), as well as its extremely promising WP1066 and WP1122 portfolios of molecules. WP1066 is designed to defeat cancer by modulating cancer progression transcription factors (WP1066), while WP1122 has been shown to actively manipulating cancer’s metabolic envelope via a novel glucose decoy technology invented by the company’s scientific founder, Dr. Waldemar Priebe.

The broad-spectrum potential of the WP1122 portfolio was heavily underscored by the announcement in late June that MBRX had identified new properties of a modified WP1122 compound (known as WP1234) that could help stamp out pancreatic cancer. The global treatment market for this cancer was recently forecast to hit somewhere around $4.2 billion by 2025, rising sharply from just $1.7 billion in 2015 (there were nearly 412,000 deaths from pancreatic cancers that year) due to factors such as a growing geriatric population and increasing rates of obesity, smoking, and excessive alcohol consumption. Shares of MBRX rose to $3.28 on June 28 given the strength of the news, as well as the announcement of an agreement with a physician at the prestigious Mayo Clinic in Rochester, Minnesota, to enable additional research into WP1066 for a rare form of pediatric brain tumor.

WP1234 showed both improved drug characteristics over WP1122 and a 20-fold to 50-fold more powerful cancer cell line-killing ability than traditional glycolysis inhibitors in preclinical testing. Because tumors are so reliant on glycolysis for energy, WP1234 could become a breakaway indication for what is still largely considered an untreatable disease. Notably, this disease has an 80 percent or greater mortality rate and will see nearly 54,000 diagnoses this year alone in the U.S., according to ACA projections.

WP1234’s apparent efficacy in pancreatic cancers owes a great deal to the ongoing collaboration with MD Anderson Cancer Center, and the enhanced cellular uptake/retention characteristics associated with the blood brain barrier-crossing WP1122 platform technology. The platform technology was designed to enable 2-DG (the molecule uptaken by cellular glucose transporters) accumulation in the brain at significantly higher levels than normal and tackle a wide variety of solid tumors; even difficult-to-treat and often progressively resistant to treatment brain tumors, like glioblastomas. The Glioblastoma multiforme treatment market is on track to run around 10.9 percent CAGR through 2025 when it will reach over $1 billion in revenues for the first time in history, according to a recent report from Brisk Insights. With notable players like Merck’s (NYSE: MRK) Temodar® or Roche’s (OTCQX: RHHBY) Avastin® currently the standard of care, humble MBRX might appear to some investors as David taking on Goliath.

The company announced on July 25 that it would support acceleration of a physician-sponsored Investigational New Drug application to clinically study WP1066 in glioblastomas. Modeled after a natural compound with tumor-fighting properties, WP1066 appears to not only supercharge a patient’s natural ability to stave off tumor development through stimulation of the immune system, it also attacks tumors directly by inhibiting the master regulator of a wide range of tumors known as STAT3 (transcription factor). And it does so in a way which bypasses the multifactorial activation of STAT3, directly and independently from upstream effectors. This means it is possible that WP1066 could hit a variety of targets, irrespective of their upstream method of activation, delivering a powerful one-two punch of direct and indirect action against tumors.

Potential AML Blockbuster

This is pretty exciting stuff already, without even really talking about the company’s lead drug for AML. On that note, Annamycin is being geared up for clinical trials, with Moleculin recently signing a brand new license agreement with MD Anderson to clear the way for key patent applications and ensure that the collaboration has a bright future. According to the American Cancer Society’s 2017 estimates, AML will make up roughly 34.4 percent of all the 62,130 projected new leukemia cases, and will lead to around 10,590 deaths this year.

A roughly $1.85 billion market last year in just North America, leukemia treatments are expected to hit upwards of $2.83 billion by 2021, clocking in at around 8.9 percent CAGR. Globally, this will most likely become a $12 billion market by 2022. More specifically, the global AML segment of this market was recently forecast to hit $1.2 billion by the end of 2023, growing at a 5.3 percent CAGR, according to one study.

And Annamycin has several significant advantages that set MBRX up for either breakout success, or a buyout by a sector major. First of all we have the elephant in the room: cardiotoxicity (which damages heart muscle) associated with antiquated anthracycline induction therapies. These therapies have been yielding about the same success rate (20 percent) as they did when first developed back in the 70s, according to MBRX. Induction therapy always includes an anthracycline like doxorubicin, which, while an important discovery in its day and still useful, is also cardiotoxic. Not only is this factor the leading cause of having to limit the dose, tumor cells also have a tendency (via the phenomena known as multidrug resistance) to develop resistivity to first-line anthracyclines, which invalidates the therapy altogether.

A unique liposome formulated anthracycline, Annamycin is engineered to avoid triggering multidrug resistance mechanisms and has been shown to be non-cardiotixic in animal models when compared directly with doxorubicin. The global doxorubicin market was worth almost $810 million in 2015, according to a report out late last year from Grand View Research, and appears on-track to do 6.4 percent CAGR through 2024. Annamycin posted solid efficacy numbers in its Phase 1 and 1/2 patient studies, with around half the patients clearing their leukemic blasts to the point where they qualify for a bone marrow transplant, and it was shown to be more potent than the leading approved drug in lab studies on AML cell lines.

Annamycin is very exciting for AML patients who must first go through induction therapy in order to qualify for a life-saving bone marrow transplant. And because the drug may serve a serious unmet medical need, the FDA may approve accelerated status. If the conversations thus far with FDA are any indication, MBRX could be sitting on a winner. If Annamycin qualifies for Orphan Drug Status, MBRX could be looking at up to a decade of market exclusivity in the two biggest AML therapy markets on earth, the U.S. and EU. By deliberately targeting approval for Annamycin as a second-line therapy, in a market where there is currently no approved second-line therapy and where around 80 percent of AML patients fail first-line therapies, MBRX has set itself up for serious momentum.

Management Has “Eye of the Tiger”

And management is clearly aware of how much potential kinetic energy exists in the company’s anti-cancer drug pipeline. This was recently demonstrated once again by doubling down on their apparently strong oncology hand with the recent tapping of product commercialization and business development veteran John M. Climaco for the Board of Directors. Climaco brings years of frontline experience on the boards of noteworthy industry players like nuclear imaging device manufacturer Digirad (NASDAQ: DRAD), oncology infusion services provider InfuSystem (NASDAQ: INFU), and biopharma sector specialized commercial services provider PDI (NASDAQ: PDII).

With so many white-hot irons in the fire, targeting underserved/unserved markets where regulatory clearance can be accelerated, this company is looking more and more like a serious contender in the space.

For more information on this company, visit www.moleculin.com